Inovio Pharmaceuticals 2025 Q1 Earnings Net Loss Narrows 35.4%

Inovio Pharmaceuticals (INO) reported its fiscal 2025 Q1 earnings on August 12, 2025. The results reflect a modest revenue increase and a significant reduction in net losses. The company’s performance showed an improvement in profitability and aligned with its strategic focus on advancing key therapeutic programs.

Inovio Pharmaceuticals reported total revenue of $65,343 for the first quarter of 2025, representing a 0.0% year-over-year increase from $0 in Q1 2024. The company’s revenue came entirely from collaborative arrangements and other contracts, which accounted for the full $65,343 in revenue.

The company successfully narrowed its losses, with net income per share improving from a loss of $1.31 in Q1 2024 to a loss of $0.51 per share in Q1 2025, representing a 61.1% improvement. Furthermore, the net loss itself decreased to $19.69 million in the first quarter of 2025, down from $30.47 million a year earlier, reflecting a 35.4% reduction in losses.

The stock price of Inovio Pharmaceuticals has shown a positive short-term performance, with a 2.05% increase during the latest trading day, a 0.68% rise during the most recent full trading week, and a notable 9.56% gain month-to-date. Despite these gains, historical post-earnings strategies have underperformed. Specifically, a strategy of buying shares after a revenue drop quarter-over-quarter on the report release date and holding for 30 days resulted in a -83.10% return over the past three years. This underperformance is significantly worse than the 46.32% benchmark return during the same period. The strategy’s excess return of -129.42% and a compound annual growth rate (CAGR) of -45.86% highlight its poor track record. Additionally, the strategy experienced a maximum drawdown of 0.00%, suggesting that the 30-day holding period may not have allowed sufficient time for recovery from initial declines in the event of a market downturn.

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer, emphasized the company’s progress on the INO-3107 Biologics License Application (BLA) submission, noting that device design verification testing is complete and the company remains on track for a second-half 2025 filing with the goal of FDA acceptance by year end. The CEO highlighted the use of the Breakthrough Therapy designation to enable rolling submission of clinical and non-clinical modules while finalizing device-related sections and updating the IND application for a confirmatory trial. She expressed optimism about the potential for INO-3107 to become a preferred treatment for Recurrent Respiratory Papillomatosis, with expectations to provide updates as the company works toward a potential approval in mid-2026.

INOVIO expects to submit the BLA for INO-3107 in the second half of 2025, with the goal of achieving FDA acceptance by year end. The company anticipates completing its BLA submission over the next several months and is requesting a priority review. It expects to begin enrolling patients in its placebo-controlled, randomized confirmatory trial for INO-3107, which includes 100 patients across 20 U.S. sites, after updating its active IND. The company also expects to present data on INO-3107 and other DNA medicine candidates at various upcoming industry conferences.

Despite the reduction in net losses, the EPS remains negative, indicating that the company is still operating at a loss and has not yet reached profitability.

The additional news section highlights developments across Nigeria, including political discourse, public health challenges, and infrastructure initiatives. On August 13, 2025, the Chief of Army Staff, Lt. Gen. Olufemi Oluyede, urged citizens to play a role in combating insurgency. The Nigerian Correctional Service revealed a mental health crisis, with 8,244 mentally ill inmates in custody. Anambra State Governor Charles Soludo reaffirmed his support for President Bola Tinubu, citing a 22-year friendship and the President’s economic reforms. The Nigerian Air Force reported significant operations in Borno, and Schneider Electric was named the World’s Most Sustainable Company by TIME and Statista. Meanwhile, political parties in Imo State called on members to remain loyal, while Ebonyi State parents criticized a university for increasing tuition fees.